- Home
- PETS vs MIRA Comparison
PETS vs MIRA Comparison
Compare PETS & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | MIRA |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 53.2M |
| IPO Year | 2003 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PETS | MIRA |
|---|---|---|
| Price | $2.31 | $1.08 |
| Analyst Decision | Sell | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.20 | N/A |
| AVG Volume (30 Days) | 88.1K | ★ 150.6K |
| Earning Date | 02-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.92 | ★ 20.31 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $0.81 |
| 52 Week High | $4.32 | $2.45 |
Technical Indicators
Market Signals| Indicator | PETS | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 27.16 | 43.55 |
| Support Level | N/A | N/A |
| Resistance Level | $2.93 | $1.28 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 8.25 | 58.82 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.